{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:24:21Z","timestamp":1790515461400,"version":"4.1.0"},"reference-count":214,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.bcp.2017.05.009","type":"journal-article","created":{"date-parts":[[2017,5,16]],"date-time":"2017-05-16T01:30:21Z","timestamp":1494898221000},"page":"10-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Challenges and opportunities for the development of new antipsychotic drugs"],"prefix":"10.1016","volume":"143","author":[{"given":"Carlos","family":"Forray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimund","family":"Buller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2017.05.009_b0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0010","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1046\/j.1440-1614.2003.01234.x","article-title":"The experience of recovery from schizophrenia: towards an empirically validated stage model","volume":"37","author":"Andresen","year":"2003","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0015","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.cpr.2008.03.004","article-title":"A scientific agenda for the concept of recovery as it applies to schizophrenia","volume":"28","author":"Silverstein","year":"2008","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.bcp.2017.05.009_b0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/wps.20194","article-title":"Recovery, not progressive deterioration, should be the expectation in schizophrenia","volume":"14","author":"Zipursky","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/10401230591002002","article-title":"History of the discovery and clinical introduction of chlorpromazine","volume":"17","author":"Lopez-Munoz","year":"2005","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0030","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/bmj.2.4887.560","article-title":"Effect of chlorpromazine on the behavior of chronically overactive psychotic patients","volume":"2","author":"Elkes","year":"1954","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bcp.2017.05.009_b0035","first-page":"451","article-title":"Neuroleptics and extrapyramidal reactions in psychiatric patients","volume":"20","author":"Ayd","year":"1961","journal-title":"Rev. Can. Biol."},{"key":"10.1016\/j.bcp.2017.05.009_b0040","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.brainresbull.2009.01.005","article-title":"The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice","volume":"79","author":"Lopez-Munoz","year":"2009","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","article-title":"Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain","volume":"20","author":"Carlsson","year":"1963","journal-title":"Acta Pharmacol. Toxicol. (Copenh)"},{"key":"10.1016\/j.bcp.2017.05.009_b0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1176\/jnp.8.2.223","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"8","author":"Creese","year":"1996","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0055","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.1145194","article-title":"Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons","volume":"188","author":"Seeman","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.bcp.2017.05.009_b0060","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"Dopamine in schizophrenia: a review and reconceptualization","volume":"148","author":"Davis","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 12","key":"10.1016\/j.bcp.2017.05.009_b0065","first-page":"22","article-title":"A historical perspective of clozapine","volume":"60","author":"Hippius","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0070","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/070674379904400303","article-title":"A comparative review of new antipsychotics","volume":"44","author":"Blin","year":"1999","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0080","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0140-6736(97)22018-0","article-title":"Olanzapine: a novel atypical neuroleptic agent","volume":"349","author":"Reus","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2017.05.009_b0085","first-page":"137","article-title":"Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics","volume":"25","author":"Stip","year":"2000","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0090","first-page":"275","article-title":"Understanding antipsychotic \u201catypicality\u201d: a clinical and pharmacological moving target","volume":"28","author":"Remington","year":"2003","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.mp.4000327","article-title":"A new framework for investigating antipsychotic action in humans: lessons from PET imaging","volume":"3","author":"Kapur","year":"1998","journal-title":"Mol. Psychiatry"},{"issue":"Suppl.","key":"10.1016\/j.bcp.2017.05.009_b0100","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2152\/jmi.52.284","article-title":"Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist","volume":"52","author":"Hirose","year":"2005","journal-title":"J. Med. Invest."},{"key":"10.1016\/j.bcp.2017.05.009_b0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2017.05.009_b0110","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0115","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-25761-2_2","article-title":"Role of dopamine D(2) receptors for antipsychotic activity","author":"Ginovart","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bcp.2017.05.009_b0125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1517\/14728214.13.3.479","article-title":"Emerging drugs for schizophrenia","volume":"13","author":"Agid","year":"2008","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.bcp.2017.05.009_b0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1600-0447.1975.tb00022.x","article-title":"A long-term follow-up study of schizophrenia: psychiatric course of illness and prognosis","volume":"52","author":"Huber","year":"1975","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bcp.2017.05.009_b0135","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/schbul\/6.4.606","article-title":"Catamnestic long-term study on the course of life and aging of schizophrenics","volume":"6","author":"Ciompi","year":"1980","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0140","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1176\/ajp.151.10.1409","article-title":"One hundred years of schizophrenia: a meta-analysis of the outcome literature","volume":"151","author":"Hegarty","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archpsyc.1991.01810270051007","article-title":"National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome","volume":"48","author":"Breier","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0150","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-0447.1990.tb06486.x","article-title":"Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?","volume":"81","author":"Helgason","year":"1990","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bcp.2017.05.009_b0155","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4088\/JCP.15m10278","article-title":"The Economic Burden of Schizophrenia in the United States in 2013","volume":"77","author":"Cloutier","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0160","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1176\/ajp.132.12.1237","article-title":"Overview: maintenance therapy in psychiatry: I","volume":"132","author":"Davis","year":"1975","journal-title":"Schizophrenia. Am J Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0165","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/schbul\/6.1.70","article-title":"Important issues in the drug treatment of schizophrenia","volume":"6","author":"Davis","year":"1980","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0170","first-page":"322","article-title":"The current status of neuroleptic therapy","volume":"50","author":"Kane","year":"1989","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl.","key":"10.1016\/j.bcp.2017.05.009_b0175","first-page":"13","article-title":"Prediction of outcome in first-episode schizophrenia","volume":"54","author":"Lieberman","year":"1993","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1176\/ajp.154.4.475","article-title":"Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance","volume":"154","author":"Meltzer","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007999709113338","article-title":"Treatment-resistant schizophrenia\u2013the role of clozapine","volume":"14","author":"Meltzer","year":"1997","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.bcp.2017.05.009_b0190","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0022-3956(97)00052-6","article-title":"The natural history and pathophysiology of treatment resistant schizophrenia","volume":"32","author":"Sheitman","year":"1998","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bcp.2017.05.009_b0195","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/schbul\/6.4.592","article-title":"Longitudinal studies of schizophrenic patients","volume":"6","author":"Huber","year":"1980","journal-title":"Schizophr. Bull."},{"issue":"Suppl. 11","key":"10.1016\/j.bcp.2017.05.009_b0200","first-page":"68","article-title":"Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis","volume":"57","author":"Lieberman","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0205","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","article-title":"Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome","volume":"151","author":"Lieberman","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0210","first-page":"126","article-title":"Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: a meta-analysis of randomized clinical trials","volume":"4","author":"Darba","year":"2011","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"10.1016\/j.bcp.2017.05.009_b0215","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0220","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.145.5.578","article-title":"Deficit and nondeficit forms of schizophrenia: the concept","volume":"145","author":"Carpenter","year":"1988","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0225","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0447.1994.tb05827.x","article-title":"Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits","volume":"380","author":"Schooler","year":"1994","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.bcp.2017.05.009_b0230","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1176\/ajp.156.3.406","article-title":"Empirical validation of primary negative symptoms: independence from effects of medication and psychosis","volume":"156","author":"Kelley","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0235","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/npp.2015.3","article-title":"Antipsychotics and amotivation","volume":"40","author":"Fervaha","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2017.05.009_b0240","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.euroneuro.2013.10.017","article-title":"Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders","volume":"24","author":"Foussias","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2017.05.009_b0245","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0250","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1001\/archpsyc.1994.03950020048005","article-title":"Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia","volume":"51","author":"Saykin","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0255","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1176\/ajp.151.1.40","article-title":"The neuropsychological signature of schizophrenia: generalized or differential deficit?","volume":"151","author":"Blanchard","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0260","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1037\/0894-4105.12.3.426","article-title":"Neurocognitive deficit in schizophrenia: a quantitative review of the evidence","volume":"12","author":"Heinrichs","year":"1998","journal-title":"Neuropsychology"},{"key":"10.1016\/j.bcp.2017.05.009_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.07.008","article-title":"Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study","volume":"105","author":"Hawkins","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2017.05.009_b0270","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0920-9964(03)00213-5","article-title":"Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia","volume":"68","author":"Hill","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2017.05.009_b0275","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1176\/ajp.156.9.1336","article-title":"Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia","volume":"156","author":"Hoff","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0280","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0285","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1037\/0021-843X.98.4.367","article-title":"Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia","volume":"98","author":"Spohn","year":"1989","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.bcp.2017.05.009_b0290","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/schbul\/16.3.477","article-title":"Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients","volume":"16","author":"Cassens","year":"1990","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0295","first-page":"353","article-title":"Antipsychotic medication effects on neuropsychological functions","volume":"28","author":"Bilder","year":"1992","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0300","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","article-title":"The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis","volume":"25","author":"Keefe","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0305","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0310","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archpsyc.64.10.1115","article-title":"Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?","volume":"64","author":"Goldberg","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0315","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2006.08.021","article-title":"A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects","volume":"89","author":"Woodward","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2017.05.009_b0320","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pbb.2011.03.011","article-title":"Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target","volume":"99","author":"Barak","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2017.05.009_b0325","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1176\/appi.ajp.2010.10060855","article-title":"A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes","volume":"168","author":"Wykes","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0330","unstructured":"Kraepelin E. Psychiatrie. Ein Lehrbuch f\u00fcr Studierende und \u00c4rzte. [5], 798\u2013814. 1896. Leipzig, J.A.Barth."},{"issue":"Pt 4","key":"10.1016\/j.bcp.2017.05.009_b0335","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/brain\/122.4.593","article-title":"The neuropathology of schizophrenia. A critical review of the data and their interpretation","volume":"122","author":"Harrison","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2017.05.009_b0340","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","article-title":"Implications of normal brain development for the pathogenesis of schizophrenia","volume":"44","author":"Weinberger","year":"1987","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0345","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/bmj.295.6600.681","article-title":"Is schizophrenia a neurodevelopmental disorder?","volume":"295","author":"Murray","year":"1987","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.bcp.2017.05.009_b0350","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1985.01790310046006","article-title":"Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage","volume":"42","author":"Bogerts","year":"1985","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0355","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1192\/bjp.151.6.744","article-title":"Post-mortem study of chronic schizophrenic brains","volume":"151","author":"Pakkenberg","year":"1987","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0360","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuroscience.2015.06.028","article-title":"The neuropathology of schizophrenia: A selective review of past studies and emerging themes in brain structure and cytoarchitecture","volume":"303","author":"Bakhshi","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2017.05.009_b0365","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1192\/bjp.186.1.18","article-title":"Predicting schizophrenia: findings from the Edinburgh High-Risk Study","volume":"186","author":"Johnstone","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0370","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sbn025","article-title":"Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology","volume":"35","author":"Fornito","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0375","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.59.6.553","article-title":"Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain?","volume":"59","author":"Weinberger","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl. 12","key":"10.1016\/j.bcp.2017.05.009_b0380","first-page":"9","article-title":"Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia","volume":"60","author":"Lieberman","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0385","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.biopsych.2011.01.032","article-title":"Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies","volume":"70","author":"Olabi","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0390","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biopsych.2007.01.004","article-title":"Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood","volume":"63","author":"van Haren","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0395","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.mp.4001558","article-title":"Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence","volume":"10","author":"Harrison","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0400","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1093\/brain\/awn211","article-title":"Auditory cortex asymmetry, altered minicolumn spacing and absence of ageing effects in schizophrenia","volume":"131","author":"Chance","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2017.05.009_b0405","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0920-9964(96)00079-5","article-title":"Is schizophrenia a lifetime disorder of brain plasticity, growth and aging?","volume":"23","author":"Delisi","year":"1997","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2017.05.009_b0410","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1176\/ajp.155.12.1661","article-title":"Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism","volume":"155","author":"Woods","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0415","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.neubiorev.2013.06.001","article-title":"Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies","volume":"37","author":"Fusar-Poli","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bcp.2017.05.009_b0420","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijdevneu.2010.08.003","article-title":"Insights into the neurodevelopmental origin of schizophrenia from postmortem studies of prefrontal cortical circuitry","volume":"29","author":"Beneyto","year":"2011","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0425","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","article-title":"Cortical inhibitory neurons and schizophrenia","volume":"6","author":"Lewis","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0430","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0006-3223(98)00281-9","article-title":"The reduced neuropil hypothesis: a circuit based model of schizophrenia","volume":"45","author":"Selemon","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0435","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2990.1999.00162.x","article-title":"No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study","volume":"25","author":"Falkai","year":"1999","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.bcp.2017.05.009_b0440","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.neuro.25.112701.142754","article-title":"Schizophrenia as a disorder of neurodevelopment","volume":"25","author":"Lewis","year":"2002","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0445","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/mp.2012.23","article-title":"Neurodevelopmental model of schizophrenia: update 2012","volume":"17","author":"Rapoport","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0450","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/sj.mp.4001642","article-title":"The neurodevelopmental model of schizophrenia: update 2005","volume":"10","author":"Rapoport","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0455","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/archgenpsychiatry.2010.66","article-title":"Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis","volume":"67","author":"Seidman","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0460","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S0140-6736(94)90569-X","article-title":"Child development risk factors for adult schizophrenia in the British 1946 birth cohort","volume":"344","author":"Jones","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2017.05.009_b0465","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0447.1999.tb05978.x","article-title":"Developmental neuropathology and the precursors of schizophrenia","volume":"395","author":"Walker","year":"1999","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.bcp.2017.05.009_b0470","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/archpsyc.1986.01800020020004","article-title":"Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence","volume":"43","author":"Weinberger","year":"1986","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0475","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/archpsyc.1986.01800020032005","article-title":"Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort","volume":"43","author":"Berman","year":"1986","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0480","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/archpsyc.1988.01800310020002","article-title":"Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. IV. Further evidence for regional and behavioral specificity","volume":"45","author":"Berman","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0485","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0306-4522(95)00051-J","article-title":"Synchronous development of pyramidal neuron dendritic spines and parvalbumin-immunoreactive chandelier neuron axon terminals in layer III of monkey prefrontal cortex","volume":"67","author":"Anderson","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2017.05.009_b0490","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/cercor\/4.1.78","article-title":"Synaptogenesis in the prefrontal cortex of rhesus monkeys","volume":"4","author":"Bourgeois","year":"1994","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.bcp.2017.05.009_b0495","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.npp.1301553","article-title":"Brain neuroplasticity in healthy, hyperactive and psychotic children: insights from neuroimaging","volume":"33","author":"Rapoport","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2017.05.009_b0500","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archpsyc.57.7.637","article-title":"Schizophrenia as a disorder of developmentally reduced synaptic connectivity","volume":"57","author":"McGlashan","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0505","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.bcp.2017.05.009_b0510","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1017\/S003329170000622X","article-title":"Does dopamine play a role in schizophrenia?","volume":"7","author":"Carlsson","year":"1977","journal-title":"Psychol. Med."},{"key":"10.1016\/j.bcp.2017.05.009_b0515","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1176\/ajp.135.2.164","article-title":"Antipsychotic drugs, neurotransmitters, and schizophrenia","volume":"135","author":"Carlsson","year":"1978","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0520","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/026988119701100205","article-title":"Dopamine, the prefrontal cortex and schizophrenia","volume":"11","author":"Knable","year":"1997","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2017.05.009_b0525","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.biopsych.2016.03.2104","article-title":"Pathway-specific dopamine abnormalities in Schizophrenia","volume":"81","author":"Weinstein","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0530","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tins.2013.11.003","article-title":"Dopaminergic basis of salience dysregulation in psychosis","volume":"37","author":"Winton-Brown","year":"2014","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0535","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/mp.2009.108","article-title":"Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis","volume":"16","author":"Fusar-Poli","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0540","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/mp.2012.109","article-title":"Striatal dopamine release in schizophrenia comorbid with substance dependence","volume":"18","author":"Thompson","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0545","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/npp.2013.347","article-title":"Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use","volume":"39","author":"Mizrahi","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2017.05.009_b0550","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.biopsych.2011.10.009","article-title":"Increased stress-induced dopamine release in psychosis","volume":"71","author":"Mizrahi","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0555","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment","volume":"69","author":"Howes","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0560","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0565","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1192\/bjp.bp.113.132308","article-title":"Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies","volume":"204","author":"Kambeitz","year":"2014","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0570","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.biopsych.2015.12.028","article-title":"Novel dopamine therapeutics for cognitive deficits in schizophrenia","volume":"81","author":"Arnsten","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0575","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0165-0173(98)00019-8","article-title":"What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?","volume":"28","author":"Berridge","year":"1998","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.bcp.2017.05.009_b0580","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrn.2015.26","article-title":"Dopamine reward prediction-error signalling: a two-component response","volume":"17","author":"Schultz","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0585","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1523\/JNEUROSCI.5310-10.2011","article-title":"Aversive stimuli alter ventral tegmental area dopamine neuron activity via a common action in the ventral hippocampus","volume":"31","author":"Valenti","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0590","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0924-9338(02)00628-4","article-title":"Dopaminergic dysfunction in alcoholism and schizophrenia\u2013psychopathological and behavioral correlates","volume":"17","author":"Heinz","year":"2002","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0595","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/schbul\/sbp049","article-title":"From real-world events to psychosis: the emerging neuropharmacology of delusions","volume":"35","author":"Morrison","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0600","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1176\/appi.ajp.160.1.13","article-title":"Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia","volume":"160","author":"Kapur","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0605","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/schbul\/sbs155","article-title":"The phenomenology and neurobiology of delusion formation during psychosis onset: Jaspers, Truman symptoms, and aberrant salience","volume":"39","author":"Mishara","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0610","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2013the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0615","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/schbul\/sbq031","article-title":"Dopaminergic dysfunction in schizophrenia: salience attribution revisited","volume":"36","author":"Heinz","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0620","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 3","key":"10.1016\/j.bcp.2017.05.009_b0625","first-page":"29","article-title":"Glutamate pharmacology and the treatment of schizophrenia: current status and future directions","volume":"10","author":"Tamminga","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2017.05.009_b0630","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1176\/appi.ajp.158.9.1367","article-title":"The emerging role of glutamate in the pathophysiology and treatment of schizophrenia","volume":"158","author":"Goff","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0635","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0640","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","article-title":"Glutamate receptor dysfunction and schizophrenia","volume":"52","author":"Olney","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0645","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1046\/j.1460-9568.2003.02902.x","article-title":"Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism","volume":"18","author":"Harris","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0650","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2174\/138920112800784899","article-title":"Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia","volume":"13","author":"McCullumsmith","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.bcp.2017.05.009_b0655","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/npp.2011.267","article-title":"Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia","volume":"37","author":"Funk","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2017.05.009_b0660","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nm.2315","article-title":"Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors","volume":"17","author":"Pitcher","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2017.05.009_b0665","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.schres.2013.12.013","article-title":"Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings","volume":"152","author":"Poels","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2017.05.009_b0670","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamapsychiatry.2013.289","article-title":"Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study","volume":"70","author":"Fuente-Sandoval","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0675","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/archgenpsychiatry.2011.1519","article-title":"Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy","volume":"69","author":"Kegeles","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0680","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/schbul\/sbr069","article-title":"Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies","volume":"39","author":"Marsman","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b0685","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.2174\/138161209788957438","article-title":"Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia","volume":"15","author":"Stone","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2017.05.009_b0690","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2017.05.009_b0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0893-133X(01)00225-1","article-title":"GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder","volume":"25","author":"Benes","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2017.05.009_b0700","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.mp.4002011","article-title":"Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia","volume":"13","author":"Hashimoto","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0705","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/appi.ajp.2007.07081223","article-title":"Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia","volume":"165","author":"Hashimoto","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0710","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/dneu.20825","article-title":"The chandelier neuron in schizophrenia","volume":"71","author":"Lewis","year":"2011","journal-title":"Dev. Neurobiol."},{"key":"10.1016\/j.bcp.2017.05.009_b0715","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tins.2011.10.004","article-title":"Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia","volume":"35","author":"Lewis","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0720","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1515\/revneuro-2011-0059","article-title":"The role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophrenia","volume":"23","author":"Rotaru","year":"2012","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0725","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tins.2008.02.005","article-title":"Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia","volume":"31","author":"Lisman","year":"2008","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0730","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coph.2014.01.001","article-title":"Schizophrenia: from dopaminergic to glutamatergic interventions","volume":"14","author":"Laruelle","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bcp.2017.05.009_b0735","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.neuropharm.2011.05.011","article-title":"Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia","volume":"62","author":"Grace","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2017.05.009_b0740","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archgenpsychiatry.2009.115","article-title":"Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders","volume":"66","author":"Schobel","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0745","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0165-6147(93)90107-U","article-title":"Metabotropic glutamate receptors in brain function and pathology","volume":"14","author":"Schoepp","year":"1993","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2017.05.009_b0750","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","article-title":"Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system","volume":"299","author":"Schoepp","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2017.05.009_b0755","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","article-title":"Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo","volume":"150","author":"Stauffer","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2017.05.009_b0760","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.06.002","article-title":"Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia","volume":"66","author":"Kinon","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2017.05.009_b0765","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia","volume":"78","author":"Kinon","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0770","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","article-title":"A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia \u2013 results from the Candle Lyte study","volume":"24","author":"Bugarski-Kirola","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2017.05.009_b0775","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"Bugarski-Kirola","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0780","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/nn.4409","article-title":"The road to precision psychiatry: translating genetics into disease mechanisms","volume":"19","author":"Gandal","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0785","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/nn.4411","article-title":"Translating genome-wide association findings into new therapeutics for psychiatry","volume":"19","author":"Breen","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0790","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd4051","article-title":"Validating therapeutic targets through human genetics","volume":"12","author":"Plenge","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2017.05.009_b0795","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2015.1735","article-title":"Opportunities for new drug development in psychiatry: a glass half-full","volume":"72","author":"O'Donnell","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0800","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Ripke","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.05.009_b0805","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/mp.2015.16","article-title":"Evaluating historical candidate genes for schizophrenia","volume":"20","author":"Farrell","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0810","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.1155174","article-title":"Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia","volume":"320","author":"Walsh","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bcp.2017.05.009_b0815","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/hmg\/ddp043","article-title":"Support for the involvement of large copy number variants in the pathogenesis of schizophrenia","volume":"18","author":"Kirov","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2017.05.009_b0820","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/mp.2011.154","article-title":"De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia","volume":"17","author":"Kirov","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0825","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.neuron.2011.11.007","article-title":"High frequencies of de novo CNVs in bipolar disorder and schizophrenia","volume":"72","author":"Malhotra","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2017.05.009_b0830","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1176\/appi.ajp.2010.10060876","article-title":"Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications","volume":"168","author":"Levinson","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0835","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/ng.3050","article-title":"A framework for the interpretation of de novo mutation in human disease","volume":"46","author":"Samocha","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2017.05.009_b0840","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.05.009_b0845","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature12975","article-title":"A polygenic burden of rare disruptive mutations in schizophrenia","volume":"506","author":"Purcell","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.05.009_b0850","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1176\/appi.ajp.2014.14020138","article-title":"The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry","volume":"171","author":"Insel","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0855","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archpsyc.60.12.1187","article-title":"Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies","volume":"60","author":"Sullivan","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0860","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1126\/science.aaa8954","article-title":"Genetics and genomics of psychiatric disease","volume":"349","author":"Geschwind","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bcp.2017.05.009_b0865","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mp.2013.50","article-title":"What psychiatric genetics has taught us about the nature of psychiatric illness and what is left to learn","volume":"18","author":"Kendler","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0870","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nn.3716","article-title":"Genome-scale neurogenetics: methodology and meaning","volume":"17","author":"McCarroll","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0875","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nn.3708","article-title":"Large-scale genomics unveils the genetic architecture of psychiatric disorders","volume":"17","author":"Gratten","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0880","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/ng.2951","article-title":"Heritability and genomics of gene expression in peripheral blood","volume":"46","author":"Wright","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2017.05.009_b0885","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature12929","article-title":"De novo mutations in schizophrenia implicate synaptic networks","volume":"506","author":"Fromer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.05.009_b0890","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/ng.2742","article-title":"Genome-wide association analysis identifies 13 new risk loci for schizophrenia","volume":"45","author":"Ripke","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2017.05.009_b0895","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/bioinformatics\/btu848","article-title":"PRSice: Polygenic Risk Score software","volume":"31","author":"Euesden","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bcp.2017.05.009_b0900","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pnpbp.2014.07.001","article-title":"Use of candidate gene markers to guide antipsychotic dosage adjustment","volume":"54","author":"Hettige","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0905","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nn.4228","article-title":"Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept","volume":"19","author":"Franke","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0910","article-title":"An examination of polygenic score risk prediction in individuals with first-episode psychosis","author":"Vassos","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0915","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/nn.4156","article-title":"The PsychENCODE project","volume":"18","author":"Akbarian","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2017.05.009_b0920","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nature10523","article-title":"Spatio-temporal transcriptome of the human brain","volume":"478","author":"Kang","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.05.009_b0925","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature10524","article-title":"Temporal dynamics and genetic control of transcription in the human prefrontal cortex","volume":"478","author":"Colantuoni","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.05.009_b0930","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.05.009_b0935","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature19847","article-title":"Chromosome conformation elucidates regulatory relationships in developing human brain","volume":"538","author":"Won","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.05.009_b0940","doi-asserted-by":"crossref","first-page":"12698","DOI":"10.1073\/pnas.0914257107","article-title":"Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways","volume":"107","author":"Miller","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2017.05.009_b0945","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.neuron.2013.10.045","article-title":"Cortical evolution: judge the brain by its cover","volume":"80","author":"Geschwind","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2017.05.009_b0950","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.biopsych.2013.08.014","article-title":"A mouse model that recapitulates cardinal features of the 15q13.3 microdeletion syndrome including schizophrenia- and epilepsy-related alterations","volume":"76","author":"Fejgin","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b0955","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.138","article-title":"Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model","volume":"40","author":"Stark","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2017.05.009_b0960","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2011.05.034","article-title":"The human brain in a dish: the promise of iPSC-derived neurons","volume":"145","author":"Dolmetsch","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2017.05.009_b0965","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neuron.2014.10.037","article-title":"Translating human genetics into novel treatment targets for schizophrenia","volume":"84","author":"Schubert","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2017.05.009_b0970","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.gde.2011.02.003","article-title":"Intermediate phenotypes in psychiatric disorders","volume":"21","author":"Rasetti","year":"2011","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.bcp.2017.05.009_b0975","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrg.2015.36","article-title":"Unravelling the human genome-phenome relationship using phenome-wide association studies","volume":"17","author":"Bush","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bcp.2017.05.009_b0980","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrg2999","article-title":"Using electronic health records to drive discovery in disease genomics","volume":"12","author":"Kohane","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bcp.2017.05.009_b0985","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \u201cjust the facts\u201d 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2017.05.009_b0990","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/NMD.0b013e318275d249","article-title":"More than one century of schizophrenia: an evolving perspective","volume":"200","author":"Silveira","year":"2012","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.bcp.2017.05.009_b0995","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-clinpsy-032813-153739","article-title":"The reliability of clinical diagnoses: state of the art","volume":"10","author":"Kraemer","year":"2014","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.bcp.2017.05.009_b1000","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev.clinpsy.3.022806.091532","article-title":"The diagnosis of mental disorders: the problem of reification","volume":"6","author":"Hyman","year":"2010","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.bcp.2017.05.009_b1005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/schbul\/sbi020","article-title":"A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia","volume":"31","author":"Buchanan","year":"2005","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b1010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1037\/0021-843X.86.2.103","article-title":"Vulnerability\u2013a new view of schizophrenia","volume":"86","author":"Zubin","year":"1977","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.bcp.2017.05.009_b1015","first-page":"53","article-title":"Renaming schizophrenia: a Japanese perspective","volume":"5","author":"Sato","year":"2006","journal-title":"World Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b1020","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1192\/bjp.129.6.574","article-title":"Toward a taxonomy of psychopathology: the purpose of psychiatric classification","volume":"129","author":"Blashfield","year":"1976","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b1025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-clinpsy-032813-153639","article-title":"The cycle of classification: DSM-I through DSM-5","volume":"10","author":"Blashfield","year":"2014","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.bcp.2017.05.009_b1030","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1741-7015-11-126","article-title":"Toward the future of psychiatric diagnosis: the seven pillars of RDoC","volume":"11","author":"Cuthbert","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.bcp.2017.05.009_b1035","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1176\/appi.ajp.2016.16030347","article-title":"The RDoC Controversy: Alternate Paradigm or Dominant Paradigm?","volume":"173","author":"Carpenter","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b1040","first-page":"i375","article-title":"\u201cSchizophrenia\u201d does not exist","volume":"352","author":"van Os","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.bcp.2017.05.009_b1045","first-page":"394","article-title":"Dementia praecox or the group of schizophrenias","volume":"21","author":"Bleuler","year":"2010","journal-title":"Vertex"},{"key":"10.1016\/j.bcp.2017.05.009_b1050","first-page":"487","article-title":"Primary & secondary symptoms in schizophrenia","volume":"25","author":"Schneider","year":"1957","journal-title":"Fortschr Neurol. Psychiatr. Grenzgeb"},{"key":"10.1016\/j.bcp.2017.05.009_b1055","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2017.05.009_b1060","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2017.05.009_b1065","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","article-title":"A systematic review and meta-analysis of recovery in schizophrenia","volume":"39","author":"Jaaskelainen","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2017.05.009_b1070","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/pcn.12322","article-title":"Schizophrenia in 2020: trends in diagnosis and therapy","volume":"69","author":"Gaebel","year":"2015","journal-title":"Psychiatry Clin. Neurosci."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217302599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217302599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T16:33:06Z","timestamp":1750264386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295217302599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":214,"alternative-id":["S0006295217302599"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2017.05.009","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and opportunities for the development of new antipsychotic drugs","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2017.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}